Sagent Pharmaceuticals Inc. (SGNT) announced the launch of Acetazolamide for Injection, USP, the generic form of the carbonic anhydrase inhibitor Diamox, in a latex-free vial presentation.
According to IMS data for the 12 months ending September 2012, the US market for Acetazolamide for Injection, USP approximated $9.5 million.
Acetazolamide for Injection, USP is indicated for adjunctive treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); and chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
For comments and feedback: editorial@rttnews.com